Li  Ding, PhD

Li Ding, PhD

Primary Academic Title

Professor of Medicine, Division of Oncology, Section of Stem Cell Biology, Washington University School of Medicine

Research Interest

Identifying and characterizing somatic/germline genetic changes relevant to cancer initiation and progression as well as drug response by integrating various data types, including DNA, RNA and proteomics data. Developing algorithms to facilitate the translation of genomic findings to clinical practice.


  • 1998: PhD, biochemistry, University of Utah, Salt Lake City


  • 1998 - 2999: Postdoctoral fellow, biochemistry, Stanford University, Palo Alto, Calif.

Selected Research Publications

Epigenetic regulation during cancer transitions across 11 tumour types.
  • Terekhanova NV, Karpova A, Liang WW, [...] Ding L
  • Nature 2023
Deep learning integrates histopathology and proteogenomics at a pan-cancer level.
  • Wang JM, Hong R, Demicco EG, [...] Ding L, [...] Fenyö D
  • Cell Rep Med 2023
Fibrosis induced by resident macrophages has divergent roles in pancreas inflammatory injury and PDAC.
  • Baer JM, Zuo C, Kang LI, [...] Ding L, [...] DeNardo DG
  • Nat Immunol 2023
Clonal Hematopoiesis and Risk of Incident Lung Cancer.
  • Tian R, Wiley B, Liu J, [...] Ding L, [...] Cao Y
  • J Clin Oncol 2023
Cancer proteogenomics: current impact and future prospects.
  • Mani DR, Krug K, Zhang B, [...] Ding L, [...] Carr SA
  • Nat Rev Cancer 2022
LINE-1 expression in cancer correlates with p53 mutation, copy number alteration, and S phase checkpoint.
  • McKerrow W, Wang X, Mendez-Dorantes C, [...] Ding L, [...] Fenyö D
  • Proc Natl Acad Sci USA 2022
Pollock: fishing for cell states.
  • Storrs EP, Zhou DC, Wendl MC, [...] Ding L
  • Bioinform Adv 2022
Genomic Profiling of Lung Adenocarcinoma in Never-Smokers.
  • Devarakonda S, Li Y, Martins Rodrigues F, [...] Ding L, Govindan R
  • J Clin Oncol 2021

View All Publications